Gene therapy for hepatocellular carcinoma: Long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo

Gene Therapy

Volumn 3, Issue 11, 1996, Pages 980-987

  Huang, H ^a   Chen, S H ^a,b   Kosai, K ^a   Finegold, M J ^a   Woo, S L C ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Adenovirus vector; Gene therapy; Hepatocellular carcinoma; Interleukin 2; Systemic antitumoral immunity

Indexed keywords

INTERLEUKIN 2;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER REGRESSION; DISSEMINATED CANCER; EXPRESSION VECTOR; GENE THERAPY; IMMUNOGENETICS; LIVER CELL CARCINOMA; METASTASIS; MOUSE; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-2; MICE; MICE, INBRED C3H; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; TUMOR CELLS, CULTURED;

ADENOVIRIDAE; ANIMALIA; MURINAE;

EID: 0029972263     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Wanebo HJ, Falkson G, Order SE. Cancer of the hepatobiliary system. In: De Vita V, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology (3 edn). Lippincott: Philadelphia, PA, 1989, pp 836-874.
2. Colombo M. Hepatocellular carcinoma. J Hepatol 1992; 15: 225-236 (review).
3. Farmer DG, Rosove MH, Shaked A, Busuttil RW. Current treatment modalities for hepatocellular carcinoma. Ann Surg 1994; 219: 236-247.
4. Venook AP. Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 1994; 12: 1323-1334 (review).
5. Maryanski JL et al. H-2 restricted cytolytic T cells specific for HLA can recognize a synthetic HLA peptide. Nature 1986; 324: 578-579.
6. Townsend ARM et al The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986; 44: 959-968.
7. Moller G. T cell stimulating factors. Immunol Rev 1980; 51: 338-357.
8. Fearon ER et al. Interleukin 2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397-403.
9. Mosmann TR, Coffman RL. Two types of mouse helper T-cell clones: implication for immune regulation. Immunol Today 1987; 8: 223-227.
10. Lotze MT et al. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 1981; 41: 4420-4425.
11. Henney CS, Kuribayashi K, Kern DE, Gilhs S. Interleukin 2 augments natural killer cell activity. Nature 1981; 291: 335-338.
12. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47: 187-376.
13. Smith KA. Interleukin 2: inception, impact and implications. Science 1988; 240: 1169-1176.
14. Parkinson DR. Interleukin 2 in cancer therapy. Semin Oncol 1988; 15: 10-26.
15. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991; 9: 694-704.
16. Gansbacher B et al Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172: 1217-1224.
17. Russell SJ et al. Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int J Cancer 1991; 47: 244-251.
18. Karp SE et al. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor. J Immunol 1993; 150: 896-908.
19. Connor J et al. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells J Exp Med 1993; 177: 1127-1134.
20. Bannerji R et al. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J Immunol 1994; 152: 2324-2332.
21. Cordier L et al. Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Therapy 1995; 2: 16-21.
22. Addison CL et al. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA 1995; 92: 8522-8526.
23. + melanoma Int Immun 1993; 5: 1501-1508.
24. Eberlein TJ, School DD. The role of interleukin 2 in cancer immunotherapy. Comp Ther 1991; 17: 49-56.
25. Rosenfeld MA et al. Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science 1991; 252: 431-434.
26. Rosenfeld MA et al In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992; 68: 143-155.
27. Haddada H et al. Adenoviral interleukin-2 gene transfer into P815 tumor cells abrogates tumorigenicity and induces antitumoral immunity in mice. Hum Gene Ther 1993; 4: 703-711
28. Ragot T et al. Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature 1993; 361: 647-650.
29. Wills KN et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 1994; 5: 1079-1088.
30. Chen SH et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo Proc Natl Acad Sci USA 1995; 92: 2577-2581.
31. Graham F. Methods in Molecular Biology: Gene Transfer and Expression Protocols, vol 7. Humana Press: New Jersey, 1991.
32. Andervont HB, Dunn TB. Transplantation of hepatomas in mice. J Natl Cancer Inst 1955; 15 (Suppl.): 1513-1524.
33. Sato H, Belkin M, Essner E. Experiments on an ascites hepatoma. III. The conversion of mouse hepatoma into the ascitic form. J Natl Cancer Inst 1956; 17: 1-21